Paris-based VC firm Kurma Partners has secured €140 million for Biofund IV, marking the first closing of the fund, which aims to support 16 to 20 startups focused on innovative therapeutics, ranging from early-stage ventures to more established companies. The fund is targeting a total of €250 million by its final closing in 2025, making it Kurma's largest venture capital investment to date. Key investors include Eurazeo, Bpifrance, and CSL.
- Founded in 2009 by Thierry Laugel, Kurma Partners is a venture capital firm managing €730 million in assets and supporting healthcare and biotech startups across Europe. To date, the firm’s portfolio includes approximately 60 startups, such as ABM Pharmareva, Amolyt Pharma, Corteria, and MedLumics.
- Kurma Partners employs a team of 25 professionals and has supported startups from their early stages through growth, focusing on early-stage biotechnology through Biofunds I, II, and III, as well as digital health and early-stage diagnostics through Kurma Diagnostics and Kurma Diagnostics 2.
- Biofund IV aims to support 16 to 20 new investments in companies that develop innovative therapeutics. The fund will focus on a balanced, risk-managed approach, investing in both startup creation and established venture-stage companies.
- The new fund has already made investments in three startups: SciRhom, which works on treatments for autoimmune diseases; Memo Therapeutics, inspired by natural immunity; and Avidicure, which focuses on cancer immunotherapy.
“With its recent portfolio company trade sales, Kurma Partners has once again demonstrated its expertise in transforming science into marketable products. Eurazeo’s participation in this new fund demonstrates our confidence in the Kurma team," Claims Olivier Millet, Member of the Executive Board and Managing Partner - Small-mid buyout & Nov Santé at Eurazeo.
- Biofund IV saw participation from several undisclosed LPs, Paris-based Eurazeo, a global investment firm managing €34.1 billion in assets, Bpifrance, and pharmaceutical industry investor CSL.
“We welcome the continued support of returning cornerstone investors, Eurazeo and Bpifrance, together with our new cornerstone pharmaceutical industry investor CSL. We are excited with the launch of Biofund IV and confident that we will continue to generate positive returns for investors and make a real impact for human health," Managing Director of Kurma Partners, Rémi Droller, commented.
